A Phase I study of TSU-68 in combination with S-1 in patients with advanced hepatocellular carcinoma who are not candidates for conventional therapy
Phase 1
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-jRCT2080221925
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Age >=20
- ECOG performance status 0-1
- Patients who did not respond to surgery, RFA, TAE
Exclusion Criteria
- Large amount of pleural effusion or ascites
- Esophageal varices
- Simultaneously active double cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method Time to progression, Response rate, Overall survival